Home / Business and Economy / Bharat Biotech Eyes $500M IPO Amid Market Slowdown
Bharat Biotech Eyes $500M IPO Amid Market Slowdown
27 Feb
Summary
- Bharat Biotech is exploring an IPO to raise over $500 million.
- The vaccine developer has supplied over 9 billion vaccines globally.
- India's IPO market faces a slow start in 2026 after record years.
Bharat Biotech International Ltd., a prominent Indian vaccine developer, is reportedly considering an initial public offering (IPO) that could potentially raise over $500 million. Discussions regarding the specifics of this potential deal, including its final size and timeline, are ongoing.
Established in 1996, Bharat Biotech has a substantial global footprint, having delivered more than 9 billion vaccines. Their product portfolio includes critical vaccines against COVID-19 and hepatitis B, alongside treatments for burns and diarrhea.
The Indian market for initial public offerings has seen a subdued beginning to 2026, following two consecutive years of record-breaking fundraising activities. Factors such as decelerating earnings growth, global trade uncertainties, and inconsistent foreign investment inflows have impacted stock performance.
